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DOI 10.1186/s12936-015-0707-2RESEARCH Open AccessThe impact of lipid-based nutrient supplementation
on anti-malarial antibodies in pregnant women in
a randomized controlled trial
Upeksha P Chandrasiri1*, Freya JI Fowkes2,3,4, Jack S Richards1,2, Christine Langer2, Yue-Mei Fan5,6, Steve M Taylor7,8,
James G Beeson1,2, Kathryn G Dewey9, Kenneth Maleta10, Per Ashorn5,6 and Stephen J Rogerson1*Abstract
Background: Malaria and undernutrition frequently coexist, especially in pregnant women and young children.
Nutrient supplementation of these vulnerable groups might reduce their susceptibility to malaria by improving
immunity.
Methods: Antibody immunity to antigens expressed by a placental-binding parasite isolate, a non-placental binding
parasite isolate, merozoites and schizonts at enrolment (before 20 gestation weeks) and at 36 gestation weeks were
measured in 1,009 Malawian pregnant women receiving a daily lipid-based nutrient supplement, multiple
micronutrients or iron and folic acid, who were participants in a randomized clinical trial assessing the effects of
nutrient supplementation on pregnancy outcomes and child development(registration ID: NCT01239693).
Results: Antibodies to placental-binding isolates significantly increased while antibodies to most merozoite antigens
declined over pregnancy. Overall, after adjustment for covariates, the type of supplementation did not influence
antibody levels at 36 gestation weeks or the rate of change in antibody levels from enrolment to 36 weeks. A
negative association between maternal body mass index and opsonizing antibodies to placental-binding antigens
(coefficient (95% CI) -1.04 (−1.84, −0.24), was observed. Similarly, women with higher socioeconomic status had
significantly lower IgG and opsonizing antibodies to placental-binding antigens. Neither of these associations was
significantly influenced by the supplementation type.
Conclusions: In the current cohort nutrient supplementation did not affect anti-malarial antibody responses, but
poor and undernourished mothers should be a priority group in future trials.
Keywords: Malaria in pregnancy, Malawi, nutrient supplements, placental-binding parasite isolate, opsonizing
antibodies, immunoglobulin G isotypes, variant surface antigens, merozoite antigens, body mass index,
socioeconomic statusBackground
It is estimated that about 125 million pregnancies world-
wide are at risk of malaria annually, significantly increas-
ing maternal and child morbidity and mortality [1].
Undernutrition is prevalent in regions where women are
at high risk of malaria in pregnancy [2]. This coexistence
of undernutrition and malaria markedly increases the
risk of adverse birth outcomes, such as intrauterine* Correspondence: upekshapc@gmail.com; sroger@unimelb.edu.au
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unless otherwise stated.growth restriction, compared to malaria or undernutri-
tion alone [3,4]. The complex relationship between
malaria and nutrition has been studied [5,6], but under-
standing of its mechanisms remains limited. Malaria in
pregnancy predisposes women to anaemia, and may re-
sult in reduced nutrient intake due to febrile illness and
anorexia. Malaria also increases susceptibility to other
infections through its immunosuppressive effects [7-9],
whilst on the other hand both macronutrient and
micronutrient deficiencies may increase the risk of in-
fections including malaria [6]. This increased suscepti-
bility is believed to be due to impairment of hosttral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment activation [11] and impaired cell mediated im-
munity [12] leading to reduced antibody production.
In endemic regions, pregnant women naturally acquire
antibodies to malaria with repeated exposure to infec-
tious mosquito bites prior to and during pregnancy.
During first pregnancies, women frequently acquire anti-
bodies to the pregnancy-specific antigens, primarily to
VAR2CSA of Plasmodium falciparum erythrocyte mem-
brane protein-1 family of variant surface antigens (VSA).
These antibodies help protect women against adverse
clinical outcomes in subsequent pregnancies [13]. How-
ever, undernourished women may have difficulty effect-
ively maintaining or acquiring antibodies against malaria
antigens.
In non-malaria-related studies both macro- and micro-
nutrient supplementation have been shown to signifi-
cantly improve pregnancy outcomes and maternal health
[14,15]. Lipid-based nutrient supplements (LNS) are
multiple micronutrient-fortified lipid-rich products that
can be beneficial as prenatal supplements in vulnerable
groups [16-18]. Prenatal LNS has been shown to im-
prove birth length [16] and reduce weight loss in HIV-
infected mothers [17], and in young HIV-exposed infants
LNS is suitable as a breast milk replacement [19]. In
addition, LNS may improve linear growth outcomes in
young children [20,21].
The only study to date that has assessed the effects of
maternal nutrient supplementation on malaria antibody
levels reported that vitamin A prenatal supplements
were associated with a reduction in antibody responses
to a placental-binding isolate EJ-24, but no significant
changes in antibody responses to non-pregnancy related
parasite isolates were observed [22].
In areas with food insecurity and high malaria trans-
mission, nutritional supplements could improve preg-
nancy outcomes and may also lead to stronger acquired
immune responses to malaria. To investigate this, anti-
body immunity was measured to antigens expressed by
placental-binding and non-placental-binding parasite
isolates, merozoite antigens and schizont extract in preg-
nant women from Mangochi, Malawi enrolled in a ran-
domized controlled trial receiving daily LNS, multiple
micronutrients (MMN - multi vitamin and minerals
combined supplement) or iron and folic acid supple-
ments (IFA – 60 mg of iron and 400 μg of folic acid).
The primary aim was to determine whether LNS supple-
mentation improved antibody responses to malaria in
pregnancy compared to IFA or MMN.
Methods
Study participants
From February 2011, 1391 pregnant women attending
four antenatal clinics in Mangochi District, Malawi wererecruited to a single-blinded randomized controlled
trial of nutrient supplementation to improve pregnancy
outcomes and child development (registration ID:
NCT01239693 [23]). Mangochi District experiences
holoendemic malaria transmission and a high preva-
lence of stunting (low height-for-age Z-score) and low
weight-for-age among infants. Women <20 gestation
weeks (gw) pregnant by ultrasound dating, aged >15 years
of age and without any chronic health conditions were en-
rolled in the study following informed consent. They were
randomly assigned to receive one tablet of IFA, one tablet
of MMN or 20 g of LNS (containing 20 mg iron and 400
μg of folic acid) daily [23]. The final maternal visit of the
trial was completed in February 2013. All participants re-
ceived two doses of sulphadoxine-pyrimethamine (SP)
malaria intermittent preventative treatment at enrolment
and at 28–34 gestation weeks [23]. The follow up of the
children of the trial is currently ongoing with the last visit
expected to complete by December 2015; for further de-
tails [23,24].Ethics approval
The trial was approved by the College of Medicine Re-
search and Ethics Committee of Malawi, and by Tampere
University Hospital Ethics Committee, Finland. Labora-
tory studies were approved by the Melbourne Health Hu-
man Research Ethics Committee.Plasma sample collection and malaria detection
Blood plasma samples were collected from participants
at study entry and at 36 gw. Malaria parasitaemia was
diagnosed by light microscopy slide positivity, PCR or
rapid diagnostic test (RDT) for asexual P. falciparum
and/or mixed Plasmodium infections at enrolment and
at 36 gw (PCR and RDT only). Parasitized red blood
cells (pRBCs) were counted microscopically against 200
leucocytes under 100 X magnification. PCR was per-
formed as previously described [25]. Briefly, genomic
DNA was extracted from dried blood spots using
Chelex®100 (Bio-Rad, CA, USA) and a quantitative real-
time PCR assay was performed to amplify the P. falcip-
arum lactate dehydrogenase (pfldh) gene. The samples
were assayed in duplicate using a Bio-Rad CFX384
Touch Real-Time PCR detection system. Concentration
of PfLDH was estimated using standard curves com-
puted from amplification curves of a series of 10 g
DNA extracts of parasite line 3D7 that were included
in each assay. RDT was performed using Clearview®
Malaria Combo (British Biocell International Ltd.,
Dundee, UK) which detects the proteins PfLDH and
histidine-rich protein 2. The prevalence of malaria in
the current cohort was 23.2% by RDT at baseline [23].
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schizont extract
Recombinant merozoite surface protein-1, MSP-1 19 kD
(3D7 clone) and full-length MSP-2 (FC27 clone) anti-
gens [26] were kindly provided by Paul Gilson (Burnet
Institute, VIC, Australia) and Robin Anders (La Trobe
University, Australia) respectively. In addition region III-
V of erythrocyte binding antigen 175 (EBA 175) [27], P.
falciparum reticulocyte binding homologue 2 (PfRh2)
(construct PfRh2-2030) [28] and the full length MSP-3
recombinant proteins were prepared following estab-
lished protocols. The schizont extract was prepared fol-
lowing the protocol described in [29].
Measuring IgG and IgG subclass antibodies to merozoite
and schizont antigens, and quantitating total plasma IgG
In brief, 0.5-2 μg/ml of each recombinant antigen was
coated on to 384 well high protein binding black Opti-
plates (PerkinElmer Inc., Massachusetts, USA). The
plates were washed with PBS/Tween 20 and non-specific
binding blocked with 0.1% casein on the following day.
The plates were then incubated with participant sera di-
luted at 1:1,000 in 0.1% casein and assayed in triplicates.
Alexa Fluor 488-conjugated goat anti-human IgG (Life
technologies, Australia) was used at 1:2,000 dilution to
detect antigen-bound IgG. The fluorescence intensity
(FI) of each well, which is proportional to the amount of
IgG bound, was measured using BMG POLARstar
Omega fluorimeter (BMG Labtech, Germany) in the
485–1 excitation and 520 emission spectra range.
Plasmas collected at enrolment and at 36 gw from 150
participants (50 from each supplementation group) were
chosen by selecting alternate pairs of samples from 4
boxes containing equal numbers of samples from the
three supplementation arms, blind to participant clinical
data. These samples were used to measure IgG subclass
antibodies to the above antigens. Antigens were coated
at the same concentration on 384 well NUNC maxisorp
plates (Thermo Fisher Scientific, VIC, Australia) and were
incubated in triplicates with plasma on the following day
at 1:250 dilution for IgG1and IgG3, and 1:50 for IgG2
and IgG4. Following incubation the plates were washed
and incubated with respective mouse anti-human sec-
ondary antibodies (IgG1 clone HP6069, IgG2 clone
HP6002, IgG3 HP6047 [Life Technologies, Australia]
and IgG4 clone HP6023 (Merck Millipore, Darmstadt,
Germany) at 1:1,000 dilution. Tertiary antibody horse-
radish peroxidase-conjugated goat anti-mouse IgG was
added at 1:2,500 dilution followed by development of
the assay using ABTS (2,2′-Azino-bis(3-ethylbenzo-
thiazoline-6-sulfonic acid); SIGMA-Aldrich). The reac-
tion was stopped using 1% sodium dodecyl sulphate,
and absorbance was read on the BMG POLARstar
Omega fluorimeter at 410 nm wavelength.The total plasma IgG in the samples of the above 150
pregnant women were measured using the fluorescence
assay method described above. Gamma-chain specific
anti-human IgG capture antibody (SIGMA-Aldrich) was
coated on to the plates at 0.5 μg/ml concentration and
incubated with participants’ plasma diluted at 1:50,000.
The concentration of IgG in each sample was deter-
mined using a purified human IgG isotype control (Life
technologies) standard curve (1 μg/ml – 0.016 μg/ml).
Serial samples were run on the same assay. The mean
FI (MFI) or optical density (OD) were reported as a per-
centage of the positive control standard curve following
adjustment for inter and intra plate variability. The posi-
tive control was a pool of plasma collected from
malaria-immune individuals. The positivity for IgG was
determined as greater than mean plus three standard de-
viations of the negative control (60 plasma samples col-
lected from Melbourne adults).
Parasites and cell culture
Placental-binding P. falciparum isolate, CS2 which binds
to chondroitin sulphate A (CSA) expressed in placenta
tissue with upregulated expression of var2csa [30] and
non-placental binding P. falciparum isolate, E8B which
binds to ICAM-1 and CD36 [31] were cultured as previ-
ously described [32]. Pro-monocytic THP-1 cells were
obtained from ATCC (Manassas, VA, USA; catalogue
number TIB-202™) and maintained as previously de-
scribed [33].
Opsonic phagocytosis assay for measuring functional
antibodies to placental-binding and non-placental-
binding malaria variant surface antigens
In order to measure antibodies that opsonize pRBCs for
phagocytic clearance a high throughput assay previously
established in the current laboratory was used [33], with
minor modifications [34], as described [32]. The per-
centage phagocytosis was determined relative to the
positive control (pRBCs incubated with a pool of sera
from patients with high levels of IgG to VSA). A partici-
pant was considered seropositive for opsonizing anti-
bodies if the percentage phagocytosis of the samples was
greater than the sum of the average and three standard
deviations of the percentage phagocytosis of the negative
controls.
Measuring IgG to variant surface antigens expressed by
placental-binding parasite isolate
Using published methods [32,35] IgG to VSA expressed
by the placental-binding isolate was measured. Alexa
Fluor® 647-conjugated donkey anti-rabbit antibody (Life
Technologies) was used as the tertiary antibody at 4
μg/ml concentration in contrast to the previous
methods. The geometric MFI of the samples were
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ability. The adjusted MFI for all samples were reported
as a percentage of the positive control. Seropositivity to
placental-binding VSA was calculated as geometric MFI
greater than the mean and three standard deviations of
the negative control.Statistical analyses
All statistical analyses were performed in Stata version
13.0 (SataCorp LP, Texas, USA). Figures were created
using GraphPad Prism 5. Statistical analyses were per-
formed according to the pre-planned analyses for the
current study approved and published in [24]. Antibody
levels were compared between supplementation groups
LNS versus IFA and LNS versus MMN using Mann
Whitney U test. Differences between antibody levels at
the two time points were determined using Wilcoxon
matched-pair test. The rate of change in antibody levels
was calculated as difference between antibody levels at
36 gw and antibody levels at enrolment divided by the
number of weeks of the study. A rate of change of 0,
suggests no change in antibody levels per week of gesta-
tion. The rate of change in antibody levels was compared
between LNS and IFA, and LNS and MMN, where IFA
and MMN were the respective reference groups, by per-
forming linear regression analysis.
Levels of antibody of each IgG subclass to merozoite
and schizont antigens were compared between supple-
mentation groups LNS versus IFA and LNS versus
MMN using Mann Whitney U test. Comparisons were
also made between antibody levels at enrolment and at
36 weeks using Wilcoxon matched-pair test.
The covariates of the association between supplemen-
tation type and malaria antibody immunity were deter-
mined based on their biological relevance. Covariates
chosen were gravidity, maternal age, HIV infection, mal-
aria infection, residence, socioeconomic status (SES),
body mass index (BMI) and antibody levels at enrol-
ment. Gravidity, maternal age, HIV and malaria infection
were previously shown to associate with malaria anti-
body immunity [36,37]. Participants’ SES was calculated
based on a scoring system for household assets (HHA)
adapted from [38]. Participants whose HHA adjusted z-
score was below the median were considered to have
low SES. Body mass index (BMI) at enrolment was cate-
gorized into three groups as low (<18.5 kg/m2); normal
(18.5-25 kg/m2) and increased (>25 kg/m2). All the vari-
ables were treated as categorical except for antibody
levels at enrolment which was treated as a continuous
variable. Likelihood ratio test was used to test whether
the association between supplementation type and anti-
body levels at 36 weeks varied with covariates chosen for
the study.Nevertheless, all of the above variables (gravidity, mater-
nal age, HIV, malaria infection at enrolment, location of
residence, SES, BMI and antibody levels at enrolment
were included in the multivariate regression models.
Multivariate linear regression analyses for continuous out-
comes (antibody levels at 36 weeks and the rate of change
in antibody levels) and multivariate logistic regression ana-
lyses for categorical outcomes (seropositivity to malaria
antigens). Differences in antibody levels among women
with different BMI and SES groups were determined fol-
lowing multivariate linear regression analysis, adjusting
for covariates including supplementation group, as de-
tailed in the table footnotes. Associations were considered
statistically significant if the p value is <0.05.
Results
Participant characteristics
Overall 1,391 women were enrolled in the iLiNS-DYAD-
M study. Malaria immunity was only measured in the
1,009 enrolment and 36 weeks paired plasma samples
that were available. The baseline characteristics of the
participants across the supplementation arms were com-
parable (Table 1). The mean (SD) gestational age in
weeks at enrolment was 16.5 (2.1) for IFA, 16.5 (2.2)
for MMN and 16.6 (2.2) for LNS groups (Table 1). Ap-
proximately 60.2% of women were multigravidae. Pro-
portion of women with BMI <18.5 kg/m2 was 5.7% and
MUAC < 23cm was 6.8%, who were identified as under-
nourished women in the current cohort. Thirteen per-
cent of women were HIV infected. The proportion of
participants lost to follow up between the supplementa-
tion groups was similar with an overall 6.04% lost to
follow up [23].
Changes in antibody levels between enrolment and 36
weeks
Opsonizing antibodies that promote phagocytic clear-
ance and IgG against the VSA expressed by placental-
binding isolate were significantly higher at 36 weeks
compared to the levels at enrolment; median relative
antibody levels, 49.7% compared to 32.7% at enrolment
(p < 0.0001) and 42.3% compared to 15.0% at enrolment
(p < 0.0001), respectively (Figure 1A). However, opsoniz-
ing antibodies to non-placental-binding isolate signifi-
cantly declined, 29.8% at 36 weeks compared to 35.4% at
enrolment (p < 0.0001) (Figure 1A). Antibody levels to
MSP-1 19kD, MSP-2, MSP-3, EBA-175 and schizont
extract were significantly reduced from enrolment to 36
weeks; median difference in relative antibody levels,
0.7% (p = 0.0006), 3.9% (p < 0.001), 0.2% (p = 0.019),
1.3% (p < 0.0001) and 6.5% (p < 0.0001), respectively
(Figure 1B). The plasma IgG levels also significantly
declined from enrolment to 36 weeks; median relative
antibody levels, 6.9% to 4.6% (p < 0.0001) (See
Table 1 Baseline characteristics of study participants
Characteristic IFA (n = 325) MMN (n = 347) LNS (n = 337) All
Gestation weeks at enrolment, mean (SD) 16.5 (2.12) 16.5 (2.23) 16.6 (2.24) 16.5 (2.20)
Age, years 23 (20–28) 24 (20–29) 24 (20–28) 24 (20–28)
Gravidity
-Primigravidae 64 (19.7%) 67 (19.2%) 68 (20.1%) 199 (19.8%)
-Secundigravidae 77 (23.7%) 64 (18.4%) 62 (18.3%) 202 (20.1%)
-Multigravidae 184 (56.6%) 214 (61.5%) 208 (61.5%) 606 (60.2%)
BMI, kg/m2; 21.5 (20.4-23.3) 21.6 (20.1-23.5) 21.7 (20.3- 23.7) 21.6 (20.3-23.5)
-BMI <18.5 kg/m2, n (%) 18 (5.6%) 18 (5.3%) 21 (6.3%) 57 (5.7%)
MUAC (cm), 26.0 (24.7-27.5) 25.7 (24.2- 27.7) 26.1 (24.6- 27.8) 26.0 (24.5-27.7)
-MUAC < 23cm, n (%) 23 (7.1%) 21 (6.1%) 24 (7.1%) 68 (6.8%)
Malaria parasitaemia
- Microscopy 34 (10.5%) 36 (10.4%) 38
(11.3%)
108 (10.7%)
- PCR 81 (25.7%) 79 (23.4%) 86
(25.7%)
246 (24.9%)
- RDT 71 (21.8%) 83 (24.1%) 75
(22.5%)
229 (22.8%)
HIV infection, n (%) 47 (14.5%) 37 (10.7%) 46 (13.6%) 130 (13.0%)
Low Socioeconomic status, n (%)a 184 (56.7%) 187 (53.9%) 189 (56.1%) 560 (55.9%)
Data presented as median (Interquartile range), or number (%) unless stated.
aSocioeconomic status calculated based on a scoring system for house hold assets. Low socioeconomic status is defined as house hold Z-score <median −0.387.
Abbreviations: SD: standard deviation; RDT: rapid diagnostic test; BMI: body mass index; MUAC: mid-upper arm circumference, PCR: Polymerase chain reaction.
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sponses to merozoite antigens and non-placental-
binding parasite isolate VSA.
Effect of nutrient supplementation on antibody immune
responses to malaria
When categorized by the supplementation groups, no sig-
nificant differences in the levels of antibody to placental-
binding or non-placental-binding isolates were observed
at 36 weeks (Figure 2A). There were also no significant
differences in antibodies to merozoite or schizont anti-
gens, when stratified by supplementation type (Figure 2B).
Following adjustment for covariates, the levels of antibody
to MSP-2 and PfRh2 at 36 weeks were significantly
lower in the LNS group compared to MMN −3.98
(−7.59, −0.37) and −4.44 (−8.85, −0.03), respectively
(See Additional file 2).
There were no differences in the prevalence of detect-
able antibody responses at 36 weeks by supplementa-
tion group (See Additional file 3). More than 85% of
the pregnant women had antibodies to placental-
binding VSA.
Effect of supplementation on the rate of change in
antibodies to malaria antigens
Significant differences in the rate of change in anti-
bodies to parasite isolate VSA were not found betweensupplementation groups (Table 2), except for MSP-2.
The rate of change in MSP-2 antibodies was signifi-
cantly negatively associated with LNS group compared
to MMN −0.25 (−0.46, −0.04) suggesting a faster de-
cline in MSP-2 antibody responses in the LNS group
(Table 2).
Modification of the association between malaria antibody
levels and supplementation group by covariates
Factors that influenced the relationship between anti-
body levels at 36 weeks and supplementation groups
were investigated. This relationship was only affected by
the antibody levels at enrolment (see Additional file 4).
Levels at enrolment of opsonizing antibodies to non-
placental binding and antibodies to MSP-2, MSP-3 and
PfRh2 at enrolment significantly influenced the relation-
ship between supplementation type and the levels of the
respective antibodies at 36 weeks (0.001 < p < 0.006;
Additional file 4). The effect modification by MSP-3
antibodies at enrolment was significant on the associ-
ation between antibodies to MSP-3 at 36 weeks between
LNS and IFA groups 3.44 (0.14, 6.75).
Effect of nutrient supplementation on IgG subclass
responses to malaria
For all the antigens tested, the highest subclass response
was for IgG3 followed by IgG1 and IgG2 with almost
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Figure 1 Antibodies to malaria antigens at enrolment and at 36 gestation weeks. (A) Antibodies to variant surface antigens expressed by
placental-binding and non-placental-binding parasite isolates. (B) Antibodies to merozoite antigens and schizont extract. Data presented as box
plots with the Y axis representing antibody levels as a percentage of the positive control. The whiskers denote the 10th and the 90th percentiles
with outliers. Wilcoxon matched pairs test performed for antibody comparisons between enrolment and 36 gestation weeks. N = 1,009.
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When categorized by the supplementation groups, sub-
class responses were not significantly different. For many
subclass responses, antibody levels declined significantly
between enrolment and 36 weeks, in keeping with the
decline in IgG to each antigen observed; this was most
apparent for IgG3 antibodies.
Influence of maternal nutrition status and socioeconomic
status on malaria antibody responses
Overall, higher levels of malaria antibodies were observed
for women with low BMI compared to the other BMI
groups (Figure 3A-C). This difference was significant for
opsonic antibodies to both placental-binding; median (p-
value), 52.8% (p = 0.005) and non-placental-binding iso-
lates 41.0% (p = 0.001) (Figure 3B-C), and was not affectedby the supplementation type. When antibody responses
were stratified by supplementation groups, significant dif-
ferences in antibody levels between BMI groups within
the same supplementation group were observed, although
these associations were not strongly consistent (Figure 3).
Following adjustment for covariates, opsonizing anti-
bodies to the placental-binding isolate, antibodies to
PfRh2 and schizont extract were significantly negatively
associated with BMI, a unit (1 kg/m2) increase in BMI is
associated with a decrease in relative antibody levels
by −1.04% (95% CI: −1.84, −0.24), −0.66% (−1.32, −0.004)
and −1.22% (−2.08, −0.37) respectively (Table 3).
In a univariate analysis, women with a low SES had
significantly higher antibody levels to VSA compared to
women with high SES, including both opsonizing anti-
bodies and IgG to placental-binding VSA (p < 0.001),
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Figure 2 Antibodies to malaria antigens at 36 weeks categorized by supplementation type. (A) Antibodies to variant surface antigens expressed by
placental-binding and non-placental-binding parasite isolates. (B) Antibodies to merozoite antigens and schizont extract. Data presented as box plots
with the Y axis representing antibodies as a percentage of the positive control. The whiskers denote the 10th and the 90th percentiles with outliers.
Mann Whitney U test performed for antibody comparisons between supplementation groups LNS versus IFA and LNS versus MMN. N = 1,009.
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(p = 0.005) (Figure 3D-F). Both IgG and opsonizing anti-
bodies to the placental-binding isolate (but not other re-
sponses) remained significantly associated with SES
following adjustment for covariates, coefficients −9.54
(−14.74, −4.35) and −5.47 (−10.43, −0.50) respectively
(Table 3).
Discussion
The association between nutrient supplementation and
malaria immunity was evaluated in 1,009 pregnant
women enrolled in a randomized controlled trial com-
paring LNS, MMN and IFA. Ingestion of LNS was not
associated with significant increases in malaria antibody
levels, a faster rate of change of antibody levels from en-
rolment to 36 weeks, or likelihood of seropositivity tomalaria antigens. This study is the first to investigate the
relationship between nutrient supplementation and mal-
aria immunity in detail.
Antibodies were measured against VSA expressed by a
placental-binding and non-placental-binding parasite
isolate, merozoite antigens and schizont extract. Anti-
bodies to placental-binding VSA reduced the risk of pla-
cental malaria by inhibiting cytoadhesion to receptors
[37], and by promoting their phagocytic clearance [39].
Antibodies to merozoite antigens can prevent invasion
of pRBCs [29] inhibit intra-erythrocytic development
and opsonize merozoites for phagocytic clearance
[40,41] contributing to the protection against clinical
malaria.
A strong increase in both total and opsonizing anti-
bodies to placental-binding VSA from study entry to 36
Table 2 Association between nutrient supplementation and the rate of change in antibody levels
Rate of change in antibody levels (Percentage antibody level change per gestation week, arbitrary
units)
LNS (n = 337) compared to IFA (n = 325) LNS (n = 337) compared to MMN (n = 347)
Unadjusted Adjusted Adjusted
p-value
Unadjusted Adjusted Adjusted
p-value
IgG to placental-binding isolate VSA −0.12 (−0.34, 0.11) −0.08 (−0.38, 0.22) 0.599 0.13 (−0.09, 0.36) 0.26 (−0.04, 0.55) 0.089
Opsonizing antibodies to
placental-binding solate VSA
−0.02 (−0.24, 0.19) −0.11 (−0.41, 0.19) 0.469 0.06 (−0.14, 0.27) 0.02 (−0.26, 0.30) 0.864
Opsonizing antibodies to
non-placental-binding isolate VSA
−0.002 (−0.12, 0.12) 0.01 (−0.16, 0.18) 0.888 −0.08 (−0.19, 0.03) 0.02 (−0.13, 0.18) 0.756
MSP-1 19kD −0.02 (−0.17, 0.12) 0.006 (−0.18, 0.19) 0.953 −0.06 (−0.19, 0.08) 0.04 (−0.14, 0.21) 0.693
MSP-2 −0.12 (−0.27, 0.03) −0.20 (−0.40, 0.02) 0.069 −0.15 (−0.32, 0.01) −0.25 (−0.46, −0.04)* 0.021*
MSP-3 −0.18 (−0.36, −0.01)* −0.21 (−0.44, 0.03) 0.080 −0.05 (−0.24, 0.14) −0.01 (−0.28, 0.27) 0.970
PfRh2 0.07 (−0.13, 0.27) 0.10 (−0.17, 0.37) 0.461 −0.21 (−0.40, −0.02)* −0.25 (−0.51, 0.02) 0.073
EBA-175 −0.06 (−0.18, 0.06) −0.04 (−0.20, 0.13) 0.639 −0.07 (−0.20, 0.05) −0.05 (−0.24, 0.14) 0.603
Schizont extract −0.03 (−0.28, 0.23) 0.13 (−0.21, 0.48) 0.450 0.003 (−0.26, 0.27) 0.10 (−0.26, 0.47) 0.583
Results presented as regression coefficients (95% confidence interval) calculated by comparing the percentage rate of change in antibody levels in LNS group
compared to IFA (reference group) and LNS group compared to MMN (reference group).
The percentage rate of change in antibody levels from enrolment to 36 gw were adjusted for gravidity, maternal age, HIV, malaria infection at enrolment, malaria
infection at 36 weeks, bed net use, body mass index at enrolment, socioeconomic status and location of residence.
Statistical test: Multivariate linear regression analysis. Data reported as regression coefficient (95% confidence interval) and p-values. *Significant associations.
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gens and non-placental-binding isolates declined. Several
explanations are possible. First, most parasite isolates in-
fecting pregnant women express antigens that are
unique and are exclusively expressed during pregnancy
[42]. Antibodies induced against such antigens may have
a longer half-life than those directed against merozoite
antigens [43]. Second, reduction in total plasma IgG at
36 weeks suggests haemodilution may have an impact
on antibody levels to non-placental-binding malaria anti-
gens; however, antibodies to tetanus and measles show
very little decline during pregnancy [43] suggesting hae-
modilution is not always a significant factor. Third, anti-
bodies to antigens expressed by a placental-binding
isolate appear to be maintained from previous pregnan-
cies, and the majority of women in the cohort were
multigravidae with high levels of these antibodies at
study entry; exposure to new infections might rapidly
boost antibody responses. By contrast, antibodies to
merozoite antigens have been reported to fluctuate
markedly with exposure during pregnancy [43]. Of note,
all participants received repeated doses of SP; parasite
resistance to this agent in Malawi is common, but not
high-grade [44]. Parasites with SP resistance demon-
strate mutations in the genes encoding P. falciparum
dihydrofolate reductase (DHFR) and dihydropteroate
(DHPS). In Malawian pregnant women quintuple muta-
tions of DHFR and DHPS are highly prevalent, however
the prevalence of more severe sextuple mutant DHPS581 which is associated with increased placental inflam-
mation is uncommon [45].
The type of supplementation had no strong or con-
sistent influence on malaria antibody levels, however a
regression analysis showed a decline in antibody re-
sponses to MSP-2 and PfRh2 from enrolment to 36
weeks, and an increased rate of reduction in antibody
levels to MSP-2, in women who received LNS com-
pared to MMN. Given the large number of compari-
sons reported, these differences in the adjusted models
could be due to chance. Similar differences in other
anti-merozoite antibodies were not observed, and the
significance of the changes is unknown. The current
study also reported the effects of nutrient supplementa-
tion on antibody responses in subsets of women at high
risk of undernutrition and infection; those with poor
nutritional status and low SES. A negative relationship
was observed between malaria antibody levels and ma-
ternal BMI and SES. Overall, women with a low BMI at
study entry had higher antibody levels to VSA than did
women with normal or increased BMI. Supplementa-
tion type did not influence the relationship between
antibody responses and BMI. Of all the antibody types
being tested the opsonizing antibodies to VSA were the
most strongly related to BMI and SES in the current
cohort, suggesting that these women might be exposed
to more malaria (Nkhoma M et al., unpublished work)
during the current pregnancy, thereby eliciting pregnancy-
specific immunity. Poorer women could have more
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Figure 3 Antibodies at 36 weeks stratified by maternal body mass index and socioeconomic status. (A-C) Antibodies to variant surface antigens of
placental-binding and non-placental-binding parasite isolates stratified by body mass index (BMI) groups and supplementation groups, (D-F) stratified by
socioeconomic status (SES) and supplementation groups. BMI groups < 18.5 kg/m2, n = 57; 18.5-25 kg/m2, n = 822; >25 kg/m2, n = 122. High SES = 441
and low SES n = 560.
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of mosquitoes, and they may be less likely to own
insecticide-treated bed nets. In addition poverty could lead
to poor nutrient intake due to inability to afford food es-
pecially during the hunger season.
The study had several limitations. The timing of nu-
tritional interventions may be critical; supplementation
starting prior to conception and continuing through
out pregnancy and lactation may offer more benefits. In
the current study the intervention started on average at
16.5 gw, following malaria peak prevalence, at around
12-17gw. Therefore the maximal benefits of the supple-
mentation on malaria antibody acquisition may have
been missed. Primigravidae constituted only 20% of
participants, limiting our ability to examine acquisition
of pregnancy-specific immunity in this group. Samples
were missing for 382 of 1,391 women enrolled. Poten-
tial causes include failure to attend the 36-week visit,
or pre-term deliveries (prior to 37 weeks). In additionunavailability of participant data for some of the covari-
ates may have reduced the power of the multiple re-
gression analyses. For analysis of BMI and malaria
immunity, stratification of participants reduced the
study power: for instance only 57 pregnant women
were in the low BMI group.
Conclusions
Overall the current study concluded that nutrient sup-
plementation of pregnant women was not associated
with broad changes in antibody responses to malaria.
This study is the first to investigate interactions be-
tween nutrition and malaria immunity in pregnancy
and further studies must be conducted to determine
the role of nutrient supplementation on other compo-
nents of host immune system such as cell-mediated
immunity, to determine the overall influence of nutri-
ent supplementation on malaria susceptibility and mal-
aria immunity.
Table 3 Relationship of maternal nutritional status and socioeconomic status to malaria antibody immunity at 36 weeks
Body mass index at enrolment (kg/m2) Socioeconomic status (high/low)
Unadjusted Adjusteda Adjusted p-valuea Unadjusted Adjustedb Adjusted p-valueb
IgG to placental-binding isolate VSA −0.88 (−1.66, −0.10)* −0.72 (−1.57, 0.12) 0.095 −13.9 (−18.25, −9.58)* −9.54 (−14.74, −4.35)* <0.001*
Opsonizing antibodies to placental-binding isolate VSA −0.86 (−1.65, −0.06)* −1.04 (−1.84, −0.24)* 0.011* −14.7 (−19.18, −10.27)* −5.47 (−10.43, −0.50)* 0.031*
Opsonizing antibodies to non-placental-binding isolate VSA −0.53 (−1.11, 0.06) 0.25 (−0.20, 0.70) 0.272 −4.07 (−7.42, −0 .70)* −0.59 (−3.38, 2.20) 0.678
MSP-1 19kD −0.08 (−0.53, 0.37) 0.45 (−0.02, 0.92) 0.060 −1.62 (−4.19, 0.96) −1.39 (−4.36, 1.57) 0.355
MSP-2 −0.40 (−0.88, 0.08) 0.14 (−0.37, 0.65) 0.595 −2.41 (−5.12, 0.30) −0.26 (−3.46, 2.94) 0.874
MSP-3 −0.01 (−0.47, 0.44) 0.06 (−0.57, 0.69) 0.856 −0.83 (−3.43, 1.77) 0.38 (−3.55, 4.31) 0.849
PfRh2 −0.30 (−0.77, 0.17) −0.66 (−1.32, −0.004)* 0.051* −0.49 (−3.17, 2.18) 0.49 (−3.64, 4.61) 0.817
EBA-175 −0.15 (−0.46, 0.16) 0.11 (−0.28, 0.50) 0.573 −1.12 (−2.89, 0.65) −0.22 (−2.66, 2.22) 0.858
Schizont extract −0.64 (−1.35, 0.07) −1.22 ( −2.08, −0.37)* 0.005* −5.17 (−9.24, −1.10)* −0.55 (−6.12, 5.01) 0.845
Data presented as regression coefficient (95% confidence interval).
aPercentage antibody levels at 36 gestation week adjusted for gravidity, maternal age, HIV, malaria infection at enrolment, bed net use, location of residence, antibody levels at enrolment, socioeconomic status,
supplementation group.
bPercentage antibody levels at 36 gestation week adjusted for gravidity, maternal age, HIV, malaria infection at enrolment, bed net use, location of residence, antibody levels at enrolment, body mass index at
enrolment, supplementation group.
Statistical test: Multivariate linear regression analysis. Data reported as regression coefficient (95% confidence interval) and p-values. *Significant associations.
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Additional file 1: Plasma IgG at enrolment and at 36 gestation
weeks. Data presented as box plot with the whiskers representing 10th
and the 90th percentiles with outliers. Y axis presents plasma IgG
concentration in g/L calculated from the standard curve created by
purified human IgG. Wilcoxon matched pair test performed for
comparison of antibody levels between enrolment and 36 weeks. Total
plasma IgG significantly reduced (p < 0.0001) by 36 weeks compared to
the levels at enrolment. Plasma IgG concentration was measured in a
subset of women (n = 150).
Additional file 2: Association between nutrient supplementation
and antibodies to malaria at 36 gestation weeks.
Additional file 3: Seropositivity to malaria antigens at 36 gestation
weeks.
Additional file 4: Antibody levels at enrolment as effect modifiers
of the relationship between antibody levels at 36 weeks and
supplementation group.
Additional file 5: IgG subclass measurements for merozoite antigens
and schizont extract at enrolment and at 36 weeks. Antibody IgG
subclasses presented as optical density (OD) measured at 410nm,
categorized by supplementation groups for antigens MSP-1 19kD, MSP-
2, MSP-3, PfRh2, EBA-175 and schizont extract (A-F). Kruskal Wallis test
performed to determine subclass level differences between supplementation
groups (IFA and LNS, MMN and LNS). Wilcoxon matched-pair test was
performed for comparing subclass levels between enrolment and 36
gw. No significant differences in subclass levels across the supplementation
groups were observed. Subclass levels at enrolment and 36 weeks were
significantly different, denoted as P < 0.05 *, p < 0.005 **, p < 0.0001 ***. IFA
(n = 50), MMN (n = 50), LNS (n = 50).Abbreviations
VSA: variant surface antigens; LNS: lipid-based nutrient supplement;
gw: gestation weeks; MMN: multiple micronutrient supplement; IFA: iron and
folic acid; HHA: household assets; SES: socioeconomic status; BMI: body mass
index; MUAC: mid-upper arm circumference; MSP: merozoite surface protein;
EBA: erythrocyte binding antigen; PfRh: Plasmodium falciparum reticulocyte
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